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ABSTRACT 
Vaccines are used as protective agents from various diseases. The major reason to prepare vaccines are to digest the macromolecule of proteins 
in stomach considering of high pH . To overcome this issue a scientist named Arntzen developed the theory of edible vaccines. EVs are 
developed by genetic technology; in this the genes are introduced directly to the plants in various methods. The developed pl ant contains coded 
protein which acts as a vaccine. Purchasing at low cost leads to the prevention of various diseases like malaria, measles, hepatitis B , cholera, 
HIV and anthrax      
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Vaccines have been revolutionary for the prevention of 
infectious diseases Vaccines. Plant-based vaccine which is 
the immune-biological substance give resistance against 
infectious and non-infectious diseases. The administration of 
a vaccine to help the immune system to develop protection 
from a disease is referred as vaccination and it is a form of 
immunization. Vaccination is given to some patients as they 
show reoccurring of the disease, there by reducing the cost 
of expensive treatment procedures. Edward Jenner is the 
father of Immunization and he was the first to study 
inoculation of cowpox virus prevents small pox in human. 
There are Various routes of administration of  vaccines, 
including oral, nasal, and parenteral routes such as 
intramuscular (IM),subcutaneous(SC), and intradermal (ID). 
Most of the commercial vaccines are administered by IM or 
SC routes. A number of new different vaccines - such as 
live/attenuated bacterial or viral vaccines, killed bacterial 
suspension, toxins produced by bacterial toxoids and 
rickettsial suspension - have been developed. 
Difficulties in traditional vaccine systems [6-7] 
The major limitations of the standard vaccines are their 
storage, transport under strictly controlled conditions. 
Criteria for standard oral vaccine system: 
i. Desired antigens should be present in sufficient quantities 
ii. Stability of expressed antigen at room temperature for a 
long time 
iii. Protective immunity must be induced by the vaccine 
iv. Should withstand degradation by enzymes in the 
stomach. 
The Evolution of plant-derived vaccine technology 
[8-10] 
The standard vaccines have many limitations and the newer 
vaccines are developing to have flexibility in administration, 
storage, transportation and ultimately cost-effective. There 
are plants and plant viruses which are genetically developed 
vaccines against diseases. Transgenic research 
developments have created production of transgenic plants 
expressing antigenic proteins as they are induced by plant 
transgenic vectors. This will help to produce special vaccines 
with high anti-disease ability. 
The positive effects of edible vaccines can decrease the 
potential hazards such as toxic compounds, responses to 
allergy, and risk of attenuated strains reverting to 
pathogenic strains. The Edible vaccines have various 
functions for either individual animals or humans by 
providing long lasting immunity without risk of relapse 
reaction and faulty techniques; there is lack of information 
about their production and mechanism of action. 
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Concept of EVs[10-14] 
The concept of edible vaccines was developed by Arntzen in 
the 1990s. Streptococcus mutans bacteria causes dental 
caries and stimulation of a mucosal immune response will 
stop the bacteria from colonizing the teeth and protects 
against tooth decay. Vaccine antigens using the methods of 
molecular biology can administrate the edible transgenic 
parts orally. The development of genes can be introduced 
into plants and expressed in the plant tissues including the 
edible components. This is known as “transformation” and 
the genetically modified plants are known as “transgenic 
plants.” The vaccine can be delivered by intake of the edible 
part of the genetically modified plant, or the high-yield 
production of refined protein for oral delivery edible 
vaccines are like unit preparations as they contain antigens, 
however, bear no genes that might change whole pathogens 
to cause serious harmful effects to humans . Thus, they don’t 
create any infection, assuring its safety, particularly in 
immune-compromised patients. The production is very 
economical, less expensive, heat stable, do not require cold 
temperature maintenance, can be stored near the site of use 
and can easily be scaled up. They don’t require syringes and 
needles, using standard methods these can be grown 
regionally and don’t require capital-intensive 
pharmaceutical manufacturing facilities. 
Properties of an ideal vaccine [15-16] 
i. It should not be toxic. 
ii. It should have very low levels of side effects in normal 
individuals. 
iii. It should not cause problems in individuals with impaired 
immune system. 
iv. It should produce long-lasting humoral and cellular 
immunities. 
v. The vaccination technique should be simple. 
vi. The vaccine should be less expensive. 
vii. No contamination in the environment. 
viii. It should be effective and affordable. 
Advantages and disadvantages of EVs [17-18] 
Advantages 
i. They can be produced economical. 
ii. They can be easily administered by eating the part of the 
plant.  
iii. They can be stored at normal room temperature. 
iv. If the local crop of a particular area produces vaccine then 
it can eliminate the distribution and transportation. 
v. They trigger the body’s first line of defense. 
Disadvantages 
i. The plants which are selected with stable antigen 
production can be a time consuming task and expensive. 
ii. Lack of knowledge about plant biotechnology leads to 
negative public opinions. 
iii. Development of oral tolerance to vaccines and difficulty 
in administration of standard dose are additional limitations. 
Mechanism of action [19-20] 
The aim of oral vaccination is to stimulate mucosal and 
systemic immunity against foreign particles. The orally 
induced edible vaccine undergoes the mastication process 
and the high amount of plant cell degradation process in the 
intestine and results in action of digestive or bacterial 
enzyme on every vaccine. The essential source of Ig A 
producing plasma cells are peyer’s patches(pp).They have 
the ability to populate mucosal tissue and provides as 
mucosal immune effector site. The collapse of edible vaccine 
near peyer’s patches consisting of 30-40 lymphoid nodules 
on the outer surface intestine and consists of follicles. This 
follicles acts as a area from which antigen penetrates the 
intestinal epithelium thereby accumulating antigen within 
organized lymphoid structure. The antigen then linked with 
M-cell. M cell crosses the antigen to macrophages and B cell. 
The T cell is activated by B cell to provide immune response. 
Immunity is activated by the edible vaccine.  
Candidates for EVs [20-25] 
Edible parts of various species of plants like grains or fruits 
are utilized for the desired interest of antigen. For high 
levels of antigenic protein expression the cereals like rice 
and maize, fruits like banana, leaves of many plants and 
tubers like potatoes, tomatoes, soybean seeds, cowpea, pea, 
carrot, peanut, and lettuce are used extensively. The factors 
considered while selecting a vehicle for the vaccine are: 
Plant must be hardy, it should be palatable, relished and it 
should be indigenous, easily available and transformation is 
done easily. The main goal of using transgenic plants as 
production systems for animal and human vaccine antigens 
is to make it easier and delivery of immunizing antigen so 
the mass immunization can be gained against infectious 
disease. 
Banana [26] 
Bananas are good choice for EV as they are sterile and do not 
pass the genes from one banana to another. Bananas grow in 
tropical climate. Most third world countries are found in this 
climate. It does not need cooking. Even if it is cooked the 
proteins are not destroyed and can be eaten raw . It is 
affordable, have high vitamin A content which boosts 
immune response and can be grown in developing countries. 
It takes 2-3years for a tree to mature and transformed tree 
takes 12 months for fruit bearing and spoils quickly after 
ripening. 
Rice [4] 
EV using genetically varied rice is used in treatment of 
cholera. Cholera vaccine is present which gives short-lived 
protection and it needs refrigeration. A strain of rice can 
serve as a vaccine and lasts more than year and half at room 
temperature. Due to low level of allergic potential it is used 
as pediatric food but grows slowly and needs specialized 
glasshouse condition. 
Maize [14] 
Maize plants produce a protein that is used to develop the 
hepatitis B virus vaccine. It is affordable and need not be 
refrigerated. A major disadvantage of this vaccine is it causes 
degradation of proteins. 
Potato [27] 
Potato based vaccine used to fight the Norwalk virus 
(stomach virus), which is spread by contaminated water and 
food and causes severe abdominal pain and diarrhea. Potato 
has been also served as a vehicle for diabetes-related 
proteins, the vaccine against a strain of Escherichia coli, 
cholera vaccine. A potato based vaccine has advantages such 
as safely stimulating antibodies, affordable, and stored for a 
prolonged period without refrigeration. The major limitation 
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is it needs cooking which can denature antigen and decrease 
immunogenicity. 
Tomato [28-30] 
Tomato as a vector develops the vaccines against anthrax, 
rabies and HIV/AIDS. It has advantages such as growing 
quickly, cultivated broadly, heat-stable, and high vitamin. A 
composition may boost immune response. Antigen which 
contains powders can be filled into capsules and with no 
requirement of storage and transportation facilities. 
However, it has a disadvantage as it spoils quickly. 
Tobacco[31-32] 
Human papilloma viruses (HPV) is the agent for causing 
cervical cancer and also skin, head, and neck tumors.  HPV 
distinct classes more than 150 are known. HPV 16 and 18 
are the most common HPVs found in cervical carcinomas.  
The E6 and E7 virus proteins are known as oncoproteins. 
Tobacco plants are a good in evaluating recombinant 
proteins and can be harvested many number times in a year. 
Due to high level toxic alkaloids composition, it causes more 
toxicity. 
Miscellaneous candidates [33-40] 
Some plants which can be served for vaccine delivery are 
lettuce , soybean  and wheat.  
APPLICATIONS OF EVs 
Malaria [40-42] 
Many strategies have been tested to fight malaria and many 
attempts have been made to introduce a malaria vaccine . 
Three antigens are in development of EVs, merozoite surface 
protein (MSP) 4 and MSP 5 from Plasmodium falciparum and 
MSP4/5 from Plasmodium yoelii. It is suggested that antigen 
response level in plants is low; this requires administration 
of a large quantity of plant material to achieve the desired 
immunity. However, due to the high degree of antigen 
expected to be necessary, it is likely that strong adjuvant 
should be required. 
Measles[43] 
The vaccine which is used currently produces 95% 
seroconversion in individuals who are over the age of 18 
months during the time of vaccination. Hence, refrigeration 
is necessary for its storage. Measles virus hemagglutinin 
(MV-H) from the antigen edmonston strain was selected for 
the development of an EV, which can be transformed into 
tobacco plant by plasmid/vector. Tobacco expression when 
it is feed to mice  MV-H could attain antibody titers 5 times 
the level is protective for humans and they also show 
secretory  IgA in their feces. It is studied that transgenic 
carrot plant is used to produce viral antigens for the 
development of measles vaccine. 
Cholera[44-45] 
Genetically modified potatoes showing CTB produces both 
serum and secretory antibodies when fed to mice. Since 
people eat only cooked potatoes, the effect of boiling on the 
properties of CTB expressed in transgenic potatoes was 
examined. It was evidenced that, over half of the vaccine 
protein survived in its biologically active form even after 
boiling for five minutes and this proves that cooking does 
not always inactivate EVs. 
Norwalk virus [46] 
Nineteen out of 20 people when administered transgenic 
potato expressing Norwalk virus antigen developed 
seroconversion. Genetically engineered bananas and 
powdered tomatoes expressing Norwalk virus are under 
development phase to fight Norwalk virus. 
HIV[47-49] 
Genetically modified tomatoes were developed by injecting 
two HIV protein genes along with promoters such as CaMV 
with a needle and the expressed protein was confirmed  by 
polymerase chain reaction in various parts of the plant, 
including the ripe fruit, as well as in the second- generation 
plant. 
Future directions 
The future of edible vaccines depends on these factors: 
• Socio-cultural acceptability of genetically changed plants, 
• Stability of genetically modified varieties and 
• Proper segregation of transgenic plants, prevention of 
environment contamination and prevention of potent side 
effects of transgenes as allergens. 
EVs can be safe and effective modes of immunization and are 
better as compared to the traditional vaccines when mass 
production, distribution, and delivery are concerned. 
Therefore, there is a need for the development of a cost-
effective, efficient and safe delivery. 
CONCLUSION 
EVs are the milestone in the branch of biotechnology for 
developing inexpensive vaccines that are particularly useful 
in immunizing people in developing countries, where high 
cost, transportation and the need for cold storage conditions, 
are hampering effective vaccination programs. Edible plant-
based vaccine may lead to a future of safer and more 
effective immunization. The expectation is that EVs may be 
fully grown in many of the developing countries where they 
would actually be used. 
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